HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Democrats Add OTC Antibody Tests To COVID-19 Fraud Questions For US Regulators

Executive Summary

Energy and Commerce Chairman Frank Pallone and four subcommittee chairs tell FTC and FDA that the degree to which COVID-19 antibodies protect against infection isn't known, but there's "significant demand for antibody tests among consumers who wish to return to their everyday activities against the advice of public health experts."

You may also be interested in...



US FDA Highlights OTC Market With Template To Boost COVID-19 Test Development

FDA template explains what information the agency wants to see in regulating COVID-19 tests to be performed outside the laboratory environment.

Consumer Health Fraud Didn’t Start With COVID-19, Senators And Witnesses Say At Hearing

“Dietary supplements are among the most poorly regulated consumer products,” CSPI policy director tells Senate Manufacturing, Trade and Consumer Protection Subcommittee. Ranking member Blumenthal says scams won’t end soon. “We’re six months into this pandemic with no end in sight.”

FDA Prioritizes Emergency-Use Reviews For Coronavirus At-Home Tests, Doubles Review Staff

A top FDA official said the agency has more than doubled its virology review staff to handle the cascade of EUA applications. He said the agency is prioritizing certain COVID-19 diagnostics during a recent webinar.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel